Bladder cancer
Conditions
Interventions
Observation group:None
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients must be 18 years or older and under 90 years old at the time of signing the informed consent form; 2. Patients must have pathologically confirmed urothelial bladder cancer; 3. Expected survival >12 months; 4. Eastern Cooperative Oncology Group performance status 0-2; 5. Patients must agree and be able to attend scheduled study visits, provide blood, urine, and surgical specimens during the specified treatment period, provide clinical information, and cooperate with other study procedures; 6. Patients must have normal organ function, a white blood cell count >= 3000/mm^3 or an absolute neutrophil count =1500/mm^3, and aspartate aminotransferase (AST. and alanine aminotransferase (ALT. <=1.5 ULN.
Exclusion criteria
Exclusion criteria: 1. Patients who, in the investigator's judgment, have other serious illnesses that may affect follow-up and short-term survival, or who have any medical condition indicating a significant risk of death during the 1-year study period. 2. Patients who have had any other malignant tumor within 3 years prior to enrollment. 3. Patients whose clinical information required for the study is unavailable. 4. Patients who, in the investigator's opinion, are otherwise unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RNA sequencing;Single-cell sequencing;Progression-Free Survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS); | — |
Countries
China
Contacts
Public ContactMinfeng Chen
Xiangya Hospital, Central South University
Outcome results
None listed